Investigational Site Number : 7240002

Córdoba 14004

1 studies enrolling now · 2 studies all time

What they study most

Alopecia Areata, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata — Stopped early